New Treatment for Immune-Related Anemia in Teens and Adults

Imaavy (nipocalimab-aahu; Patient Information pronunciation im-AH-vee) is a neonatal Fc receptor blocker — a recombinant human IgG1λ monoclonal antibody given by intravenous infusion only after dilution in 0.9% Sodium Chloride Injection. On the USPI it is labelled for two separate indications with different dose schedules:

1. gMG (USPI §1.1) — adults and pediatrics ≥12 who are AChR or MuSK antibody positive.
2. wAIHA (USPI §1.2) — adults and pediatrics ≥12 currently or previously treated with corticosteroids.

This article is about the wAIHA pathway. The gMG label is mentioned only so readers do not mix up the two schedules.

Distinct path — not this label: Other FcRn blockers and other hematology therapies exist under separate labels. Cold-agglutinin disease / cold AIHA products and cold-antibody syndromes are not this warm-AIHA indication. Today’s approved US treatment for wAIHA is Imaavy 30 mg/kg IV every 4 weeks after the initial 30 mg/kg dose. A gMG refill schedule, a Canadian gMG DIN, or an EU gMG SmPC is not this wAIHA care plan.

FDA approved the wAIHA indication as a major labeling change to BLA 761430 (USPI revised 08/2026; Reference ID 5857795). FDA news page FDA Approves First Drug for Warm Autoimmune Hemolytic Anemia is current as of 25 August 2026 (some company / AABB materials cite 24 August 2026 — this article follows the FDA news date). Applicant / manufacturer: Janssen Biotech, Inc., Horsham, PA; U.S. License Number 1864. Fast Track, priority review, and orphan designations noted on the FDA news page for this indication.

Where this is taking place

Approved wAIHA prescription route today: United States — FDA-labelled Imaavy for wAIHA in patients ≥12 years with current or prior corticosteroid treatment. This is a hematology / transfusion-medicine / infusion-clinic conversation with weight-based IV dosing, infection and hypersensitivity monitoring, and specialty-pharmacy logistics — not a retail pickup and not a DIY import.

Outside the United States for wAIHA: At the time of writing, no confirmed Health Canada, European Commission, MHRA, TGA, Swissmedic, or PMDA/MHLW wAIHA marketing authorisation for Imaavy. Canada and the EU authorise Imaavy for gMG — that is not automatic permission to use a US wAIHA schedule abroad. Do not import on your own.

wAIHA Study — NCT04119050 (USPI Study) — Phase 2/3, multicenter, randomized, double-blind, placebo-controlled with long-term open-label extension. Lead sponsor on ClinicalTrials.gov: Janssen Research & Development, LLC. CT.gov status: active but no longer taking new patients. Actual enrolment 118. Start 15 Aug 2019; actual primary completion 2 Feb 2025; estimated study completion 1 Apr 2028. Study Director on the record: Janssen Research & Development, LLC Clinical Trial. Countries with listed sites include the United States, Brazil, China, Czechia, Egypt, France, Germany, Greece, Hungary, Israel, Italy, Japan, Malaysia, Netherlands, Poland, South Korea, Spain, Ukraine, and the United Kingdom. Expanded access: A related CT.gov expanded-access record NCT05221619 is listed as temporarily not available — that is not an open enrolment or compassionate route today. Do not treat it as a current path alongside labelled US commercial use. Not a new-enrolment path for newly labelled commercial use — the pivotal efficacy population that supports the label is already enrolled; follow-up continues.

The practical route in the US is a hematology clinician who can confirm warm AIHA (vs cold / mixed / PCH), document corticosteroid history, arrange weight-based 30 mg/kg IV every 4 weeks, complete age-appropriate vaccines before start when needed, and monitor for infection, hypersensitivity, and infusion reactions — not treating NCT04119050 as open recruitment.

Approval matrix

Access by country

• United States: Ask a hematology (or transfusion-medicine) clinic about FDA-labelled Imaavy for wAIHA. Labelled for adult and pediatric patients 12 years of age and older currently or previously treated with corticosteroids. Recommended wAIHA dosage: 30 mg/kg IV once over ≥30 minutes; four weeks later 30 mg/kg IV over ≥15 minutes, then every 4 weeks. Dilute in 0.9% sodium chloride to 250 mL (≥40 kg) or 100 mL (<40 kg, age ≥12). Infuse via 0.2 micron filter. Monitor 30 minutes after each infusion. Strengths: 300 mg/1.62 mL (NDC 57894-800-01) and 1,200 mg/6.5 mL (NDC 57894-801-01). Prior authorisation and infusion-center logistics still apply. No list price or copay dollars in this article. Suspected adverse reactions: Janssen Biotech 1-800-526-7736 or FDA MedWatch 1-800-FDA-1088. This is US commercial labelled supply, not a DIY import.

• Canada: wAIHA authorisation not confirmed. Imaavy DINs exist for the gMG Product Monograph path. A Canadian gMG DIN is not a wAIHA label. Ask the Canadian hematology clinic what legal paths exist in Canada for wAIHA when a Canadian wAIHA label is not confirmed.

• European Union / United Kingdom / other countries: EU Imaavy SmPC retrieved for this article is gMG-only. wAIHA authorisation not confirmed. Trial participation is not a commercial wAIHA label.

• If your regulator has not authorised wAIHA Imaavy: do not import on your own. Ask the local hematology clinician about documented special-access / named-patient rules, referral to a centre in a labelled country, or waiting — without treating a US vial as a foreign pack.

Who is eligible (from the US label — wAIHA)

This is a wAIHA ≥12 years conversation on the USPI — current or prior corticosteroids — IV every 4 weeks at 30 mg/kg, not the gMG every-2-weeks maintenance dose.

United States (USPI / Patient Information, revised August 2026):

• Indication: Treatment of warm autoimmune hemolytic anemia (wAIHA) in adult and pediatric patients 12 years of age and older currently or previously treated with corticosteroids.
• Recommended dosage (wAIHA): Initial 30 mg/kg IV over ≥30 minutes; subsequent 30 mg/kg IV over ≥15 minutes every 4 weeks.
• Missed dose: Administer as soon as possible; resume maintaining the treatment interval.
• Vaccines: Evaluate age-appropriate vaccines before start. Live vaccines not recommended during treatment.
• Contraindication: History of serious hypersensitivity to nipocalimab-aahu or any excipient (including anaphylaxis / angioedema).
• Warnings: Infections (delay if active infection); hypersensitivity; infusion-related reactions. Monitor during infusion and for 30 minutes after.
• Drug interactions: Closely monitor medications that bind human FcRn; if long-term concomitant use is essential, consider discontinuing Imaavy and using alternatives.
• Pregnancy / lactation: Limited pregnancy data; pregnancy safety study — report exposure via Janssen contact on label. Nipocalimab excreted in colostrum/breastmilk on limited data — discuss breastfeeding with the clinician.
• Pediatrics: Safety and effectiveness for wAIHA established in ≥12 years (adult trial + PK in adolescents). Not established below age 12.
• Trial context (FDA news / USPI): diagnosis ≥3 months; Hb typically low; DAT positive; active hemolysis; prior/current wAIHA treatment required in the pivotal study (treatment-naive excluded on CT.gov criteria).

Not labelled on the sources checked for this article:

• Children under 12 for wAIHA.
• Canadian, EU, UK, Japanese, Australian, or Swiss wAIHA marketing authorisations (not confirmed here).
• Using the gMG 15 mg/kg every-2-weeks maintenance schedule for wAIHA.
• Cold AIHA / cold agglutinin syndrome / mixed AIHA / PCH under this warm indication.
• Treating NCT04119050 follow-up as open commercial enrolment.

What the pivotal study showed (wAIHA Study / USPI)

Use the USPI for a prescription conversation. Journals and conference abstracts are supportive reading.

wAIHA Study — NCT04119050:

• Randomized, double-blind, placebo-controlled, multicenter; 118 patients assigned to Imaavy 30 mg/kg q4 weeks, Imaavy 15 mg/kg q2 weeks, or placebo (FDA news). USPI efficacy table focuses on the recommended 30 mg/kg every 4 weeks arm (N=38) vs placebo (N=39).
• Primary concept: durable hemoglobin response — Hb ≥10 g/dL and increase from baseline ≥2 g/dL for ≥three consecutive visits (minimum 28 days), criteria met starting by Week 16, without rescue; discontinuations / rescue count as non-responders.
• FDA news: the 15 mg/kg arm did not beat placebo on durable response — not the labelled wAIHA regimen.

USPI Table 7 (efficacy — labelled regimen):

FACIT-Fatigue LS mean change to Week 24: +2.95 vs −0.56 placebo (LS mean difference 3.51).

NCT04119050 supports the US wAIHA label. CT.gov remains active but no longer taking new patients because follow-up continues. That is not a route for new commercial starters outside labelled US distribution. The related expanded-access listing NCT05221619 is temporarily not available, so it is not an open route.

How it is taken (US label — wAIHA)

Do not confuse with gMG dosing on the same label: gMG uses 30 mg/kg once then 15 mg/kg every 2 weeks. wAIHA keeps 30 mg/kg every 4 weeks.

Safety watchpoints (plain language)

• Infections: Imaavy lowers IgG; infections were common in trials; serious infections reported. Delay dosing for active infection; seek care for fever or infection symptoms. Live vaccines not recommended during treatment.
• Hypersensitivity: Anaphylaxis, angioedema, rash, urticaria, eczema — stop infusion and get urgent care if severe.
• Infusion-related reactions: Headache, flu-like symptoms, rash, nausea, fatigue, dizziness, chills, redness — clinic may slow or stop the drip.
• Common (≥10% in wAIHA): Peripheral edema, diarrhea, fever.
• Pregnancy / breastfeeding: Limited data; talk with the clinician before pregnancy or while nursing; pregnancy exposures can be reported to Janssen per label.

How to talk with a clinician

Bring: diagnosis details (warm vs cold AIHA; DAT results), current hemoglobin and hemolysis labs, full list of steroids / immunosuppressants / rituximab history, vaccine record, infection history, and whether you have ever had a serious reaction to Imaavy or similar infusions.

Useful questions:

1. Do I meet the labelled wAIHA ≥12 + corticosteroid criteria, and is cold/mixed disease ruled out?
2. Will you use the 30 mg/kg every-4-weeks schedule (not the gMG schedule)?
3. What infection and infusion monitoring will you use after each dose?
4. How will specialty pharmacy / prior authorisation work for the 300 mg or 1,200 mg vials?
5. If I am outside the US, what legal options exist without importing a US vial on my own?

Bottom line

Imaavy (nipocalimab-aahu) is an IV FcRn blocker and the first FDA-labelled therapy specifically for warm autoimmune hemolytic anemia in patients 12 years and older with current or prior corticosteroids. FDA action dated 25 August 2026 on the agency news page; USPI §1.2 revised 08/2026. Dose: 30 mg/kg IV then every 4 weeks. NCT04119050 durable Hb response 23.7% vs 7.7%. Watch infections, hypersensitivity, and infusion reactions. United States is the approved wAIHA prescription route on the sources checked; Canada/EU Imaavy licences are gMG, not confirmed for wAIHA. Pivotal follow-up is not a new enrolment path. Authorized is not funded.